2	0	1	B-Drug_or_compound
-	1	2	I-Drug_or_compound
methoxyestradiol	2	18	I-Drug_or_compound
inhibits	19	27	O
hypoxia	28	35	B-Gene_or_gene_product
-	35	36	I-Gene_or_gene_product
inducible	36	45	I-Gene_or_gene_product
factor	46	52	I-Gene_or_gene_product
1alpha	53	59	I-Gene_or_gene_product
,	59	60	O
tumor	61	66	B-Pathological_formation
growth	67	73	O
,	73	74	O
and	75	78	O
angiogenesis	79	91	O
and	92	95	O
augments	96	104	O
paclitaxel	105	115	B-Drug_or_compound
efficacy	116	124	O
in	125	127	O
head	128	132	B-Pathological_formation
and	133	136	I-Pathological_formation
neck	137	141	I-Pathological_formation
squamous	142	150	I-Pathological_formation
cell	151	155	I-Pathological_formation
carcinoma	156	165	I-Pathological_formation
.	165	166	O

PURPOSE	168	175	O
:	175	176	O
Head	177	181	B-Pathological_formation
and	182	185	I-Pathological_formation
neck	186	190	I-Pathological_formation
squamous	191	199	I-Pathological_formation
cell	200	204	I-Pathological_formation
carcinomas	205	215	I-Pathological_formation
have	216	220	O
been	221	225	O
reported	226	234	O
to	235	237	O
overexpress	238	249	O
hypoxia	250	257	B-Gene_or_gene_product
-	257	258	I-Gene_or_gene_product
inducible	258	267	I-Gene_or_gene_product
factor	268	274	I-Gene_or_gene_product
(	275	276	I-Gene_or_gene_product
HIF	276	279	I-Gene_or_gene_product
)	279	280	I-Gene_or_gene_product
-	280	281	I-Gene_or_gene_product
1alpha	281	287	I-Gene_or_gene_product
,	287	288	O
a	289	290	O
transcription	291	304	O
factor	305	311	O
that	312	316	O
promotes	317	325	O
expression	326	336	O
of	337	339	O
angiogenesis	340	352	O
factors	353	360	O
and	361	364	O
resistance	365	375	O
to	376	378	O
programmed	379	389	O
and	390	393	O
therapy	394	401	O
-	401	402	O
induced	402	409	O
cell	410	414	B-Cell
death	415	420	O
.	420	421	O

2	422	423	B-Drug_or_compound
-	423	424	I-Drug_or_compound
Methoxyestradiol	424	440	I-Drug_or_compound
(	441	442	O
2ME2	442	446	B-Drug_or_compound
)	446	447	O
is	448	450	O
a	451	452	O
natural	453	460	O
compound	461	469	O
with	470	474	O
HIF	475	478	B-Gene_or_gene_product
-	478	479	I-Gene_or_gene_product
1alpha	479	485	I-Gene_or_gene_product
inhibitory	486	496	O
activity	497	505	O
that	506	510	O
is	511	513	O
currently	514	523	O
being	524	529	O
evaluated	530	539	O
in	540	542	O
phase	543	548	O
1	549	550	O
and	551	554	O
2	555	556	O
clinical	557	565	O
trials	566	572	O
for	573	576	O
advanced	577	585	O
solid	586	591	B-Pathological_formation
tumors	592	598	I-Pathological_formation
and	599	602	O
multiple	603	611	O
myeloma	612	619	B-Pathological_formation
.	619	620	O

To	621	623	O
our	624	627	O
knowledge	628	637	O
,	637	638	O
this	639	643	O
is	644	646	O
the	647	650	O
first	651	656	O
study	657	662	O
to	663	665	O
evaluate	666	674	O
the	675	678	O
effects	679	686	O
of	687	689	O
2ME2	690	694	B-Drug_or_compound
in	695	697	O
head	698	702	B-Pathological_formation
and	703	706	I-Pathological_formation
neck	707	711	I-Pathological_formation
squamous	712	720	I-Pathological_formation
cell	721	725	I-Pathological_formation
carcinoma	726	735	I-Pathological_formation
.	735	736	O

EXPERIMENTAL	737	749	O
DESIGN	750	756	O
:	756	757	O
In	758	760	O
the	761	764	O
present	765	772	O
study	773	778	O
,	778	779	O
we	780	782	O
investigated	783	795	O
the	796	799	O
effects	800	807	O
of	808	810	O
2ME2	811	815	B-Drug_or_compound
alone	816	821	O
and	822	825	O
in	826	828	O
combination	829	840	O
with	841	845	O
paclitaxel	846	856	B-Drug_or_compound
,	856	857	O
an	858	860	O
active	861	867	O
agent	868	873	O
in	874	876	O
recurrent	877	886	O
or	887	889	O
advanced	890	898	O
head	899	903	B-Pathological_formation
and	904	907	I-Pathological_formation
neck	908	912	I-Pathological_formation
squamous	913	921	I-Pathological_formation
cell	922	926	I-Pathological_formation
carcinoma	927	936	I-Pathological_formation
.	936	937	O

RESULTS	938	945	O
:	945	946	O
2ME2	947	951	B-Drug_or_compound
exhibited	952	961	O
antiproliferative	962	979	O
and	980	983	O
cytotoxic	984	993	O
effects	994	1001	O
in	1002	1004	O
a	1005	1006	O
panel	1007	1012	O
of	1013	1015	O
five	1016	1020	O
head	1021	1025	B-Cell
and	1026	1029	I-Cell
neck	1030	1034	I-Cell
squamous	1035	1043	I-Cell
cell	1044	1048	I-Cell
carcinoma	1049	1058	I-Cell
cell	1059	1063	I-Cell
lines	1064	1069	I-Cell
in	1070	1072	O
the	1073	1076	O
0	1077	1078	O
.	1078	1079	O
5	1079	1080	O
to	1081	1083	O
10	1084	1086	O
micromol	1087	1095	O
/	1095	1096	O
L	1096	1097	O
range	1098	1103	O
,	1103	1104	O
including	1105	1114	O
induction	1115	1124	O
of	1125	1127	O
G2	1128	1130	O
-	1130	1131	O
M	1131	1132	O
blockade	1133	1141	O
,	1141	1142	O
caspase	1143	1150	B-Gene_or_gene_product
-	1150	1151	I-Gene_or_gene_product
3	1151	1152	I-Gene_or_gene_product
/	1152	1153	O
7	1153	1154	B-Gene_or_gene_product
activation	1155	1165	O
,	1165	1166	O
and	1167	1170	O
apoptosis	1171	1180	O
at	1181	1183	O
48	1184	1186	O
hours	1187	1192	O
.	1192	1193	O

2ME2	1194	1198	B-Drug_or_compound
resulted	1199	1207	O
in	1208	1210	O
decreased	1211	1220	O
nuclear	1221	1228	O
HIF	1229	1232	B-Gene_or_gene_product
-	1232	1233	I-Gene_or_gene_product
1alpha	1233	1239	I-Gene_or_gene_product
-	1239	1240	O
binding	1240	1247	O
activity	1248	1256	O
and	1257	1260	O
affected	1261	1269	O
the	1270	1273	O
expression	1274	1284	O
of	1285	1287	O
downstream	1288	1298	O
genes	1299	1304	O
,	1304	1305	O
such	1306	1310	O
as	1311	1313	O
bid	1314	1317	B-Gene_or_gene_product
,	1317	1318	O
a	1319	1320	O
proapoptotic	1321	1333	O
bcl	1334	1337	B-Gene_or_gene_product
-	1337	1338	I-Gene_or_gene_product
2	1338	1339	I-Gene_or_gene_product
family	1340	1346	I-Gene_or_gene_product
member	1347	1353	O
,	1353	1354	O
and	1355	1358	O
vascular	1359	1367	B-Gene_or_gene_product
endothelial	1368	1379	I-Gene_or_gene_product
growth	1380	1386	I-Gene_or_gene_product
factor	1387	1393	I-Gene_or_gene_product
,	1393	1394	O
a	1395	1396	O
proangiogenic	1397	1410	O
cytokine	1411	1419	O
.	1419	1420	O

The	1421	1424	O
up	1425	1427	O
-	1427	1428	O
regulation	1428	1438	O
of	1439	1441	O
Bid	1442	1445	B-Gene_or_gene_product
(	1446	1447	O
57	1447	1449	O
.	1449	1450	O
5	1450	1451	O
%	1451	1452	O
at	1453	1455	O
12	1456	1458	O
hours	1459	1464	O
,	1464	1465	O
P	1466	1467	O
less	1469	1473	O
than	1474	1478	O
0	1480	1481	O
.	1481	1482	O
0006	1482	1486	O
)	1486	1487	O
and	1488	1491	O
inhibition	1492	1502	O
of	1503	1505	O
vascular	1506	1514	B-Gene_or_gene_product
endothelial	1515	1526	I-Gene_or_gene_product
growth	1527	1533	I-Gene_or_gene_product
factor	1534	1540	I-Gene_or_gene_product
secretion	1541	1550	O
(	1551	1552	O
57	1552	1554	O
.	1554	1555	O
7	1555	1556	O
%	1556	1557	O
at	1558	1560	O
24	1561	1563	O
hours	1564	1569	O
,	1569	1570	O
P	1571	1572	O
less	1574	1578	O
than	1579	1583	O
0	1585	1586	O
.	1586	1587	O
015	1587	1590	O
;	1590	1591	O
and	1592	1595	O
50	1596	1598	O
.	1598	1599	O
3	1599	1600	O
%	1600	1601	O
at	1602	1604	O
48	1605	1607	O
hours	1608	1613	O
,	1613	1614	O
P	1615	1616	O
less	1618	1622	O
than	1623	1627	O
0	1629	1630	O
.	1630	1631	O
0006	1631	1635	O
)	1635	1636	O
could	1637	1642	O
be	1643	1645	O
partially	1646	1655	O
attributed	1656	1666	O
to	1667	1669	O
the	1670	1673	O
effects	1674	1681	O
on	1682	1684	O
HIF	1685	1688	B-Gene_or_gene_product
-	1688	1689	I-Gene_or_gene_product
1alpha	1689	1695	I-Gene_or_gene_product
,	1695	1696	O
because	1697	1704	O
HIF	1705	1708	B-Gene_or_gene_product
-	1708	1709	I-Gene_or_gene_product
1alpha	1709	1715	I-Gene_or_gene_product
small	1716	1721	O
interfering	1722	1733	O
RNAs	1734	1738	O
produced	1739	1747	O
similar	1748	1755	O
effects	1756	1763	O
.	1763	1764	O

Finally	1765	1772	O
,	1772	1773	O
in	1774	1776	O
vivo	1777	1781	O
,	1781	1782	O
in	1783	1785	O
a	1786	1787	O
xenograft	1788	1797	O
model	1798	1803	O
of	1804	1806	O
head	1807	1811	B-Pathological_formation
and	1812	1815	I-Pathological_formation
neck	1816	1820	I-Pathological_formation
squamous	1821	1829	I-Pathological_formation
cell	1830	1834	I-Pathological_formation
carcinoma	1835	1844	I-Pathological_formation
using	1845	1850	O
UM	1851	1853	B-Cell
-	1853	1854	I-Cell
SCC	1854	1857	I-Cell
-	1857	1858	I-Cell
11A	1858	1861	I-Cell
cells	1862	1867	I-Cell
,	1867	1868	O
2ME2	1869	1873	B-Drug_or_compound
exhibited	1874	1883	O
antitumor	1884	1893	B-Pathological_formation
and	1894	1897	O
antiangiogenic	1898	1912	O
activity	1913	1921	O
,	1921	1922	O
as	1923	1925	O
measured	1926	1934	O
by	1935	1937	O
CD31	1938	1942	B-Gene_or_gene_product
immunostaining	1943	1957	O
.	1957	1958	O

CONCLUSIONS	1959	1970	O
:	1970	1971	O
These	1972	1977	O
results	1978	1985	O
provide	1986	1993	O
support	1994	2001	O
for	2002	2005	O
the	2006	2009	O
use	2010	2013	O
of	2014	2016	O
2ME2	2017	2021	B-Drug_or_compound
in	2022	2024	O
combination	2025	2036	O
with	2037	2041	O
paclitaxel	2042	2052	B-Drug_or_compound
for	2053	2056	O
the	2057	2060	O
treatment	2061	2070	O
of	2071	2073	O
recurrent	2074	2083	O
or	2084	2086	O
advanced	2087	2095	O
head	2096	2100	B-Pathological_formation
and	2101	2104	I-Pathological_formation
neck	2105	2109	I-Pathological_formation
squamous	2110	2118	I-Pathological_formation
cell	2119	2123	I-Pathological_formation
carcinoma	2124	2133	I-Pathological_formation
.	2133	2134	O

